Summary:
The objectives of this 10-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive therapy compared with placebo in patients with MDD who have shown an inadequate response to standard antidepressant treatment. A secondary objective of this study is to assess the pharmacokinetics (PK) of AVP-786 and potential correlations with pharmacodynamic effects.
Qualified Participants Must:
• Have depression
•
Be on a single anti-depressant therapy
•
Be 18 years of age or older
Qualified Participants May Receive:
Study related care and medicine at no charge. Qualified participants may receive additional compensation for time and travel.